InspireMD Inc. (NSPR)
NASDAQ: NSPRHealth CareMedical/Dental InstrumentsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
NSPR stock chart
Technical analysisKey statistics
All statistics- Market cap
- $29.23M
- EPS (TTM)
- -$0.57
- Dividend yield
- None
- 52-week range
- 0.43 – 2.17
- Day range
- 0.4999 – 0.63
- Volume / Avg
- 633.90K / 234.68K
- Beta
- —
- Shares outstanding
- 54.13M
52-week range
NSPR stock today
On Nov 20, NSPR ended the session at $0.54, shedding $0.0805 (12.97%), versus the S&P 500's 3.70% decline. Volume was 2.7x the average at 633.90K shares, a sign of unusually heavy trading. Shares are 75.1% below their 52-week high of $2.17, set on Dec 23, 2025 and 25.6% above the 52-week low of $0.43, near the bottom of the past year's range.
NSPR is down 69.7% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 72.0%. InspireMD has posted a net loss over the last twelve months (EPS of -$0.57), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About InspireMD
Company profileInspireMD, Inc., a medical device company, focuses on the development and commercialization of products for the treatment of carotid artery disease and other vascular conditions in the United States, Germany, Italy, Russia, Poland, and internationally. It offers MicroNet, a biocompatible polymer mesh material for medical implants, as well as for treating plaque prolapse and embolization; CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Carotid Stent System; and SwitchGuard neuroprotection system to provide flow reversal of cerebral protection in carotid interventions, as well as treating acute stroke with tandem lesions. The company was founded in 2005 and is headquartered in Miami, Florida.
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
- CEO
- Mr. Marvin L. Slosman
- Headquarters
- Miami, FL
- Employees
- 127
- Website
- inspiremd.com
Financial highlights
Full financialsIn fiscal 2025, InspireMD generated $9.0 million in revenue, up 28.1% from fiscal 2024, its 5th consecutive year of revenue growth. InspireMD reported a net loss of $48.8 million, compared with a loss of $32.0 million a year earlier. Gross margin was 29.5% (up from 21.5%) and operating margin -552.6%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $8.98M | $7.01M | $6.21M | $5.17M | $4.50M |
| Growth | +28.11% | +12.96% | +20.00% | +15.04% | +80.89% |
| Net income | $-48.79M | $-32.01M | $-19.92M | $-18.49M | $-14.92M |
| EPS (diluted) | $-0.76 | $-0.76 | $-0.82 | $-2.35 | $-2.03 |
Analyst forecast
ForecastConsensus (3 analysts)
none
Avg. price target
$3.33+516.67%
- Strong buy 2
- Buy 1
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 12, 2026
- EPS actual vs est.
- $-0.17 vs $-0.15
- Surprise
- -13.33%
NSPR news
All NSPR news- InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- InspireMD Announces First U.S. Commercial TCAR Procedures Using the FDA-Approved CGuard® Prime TransCarotid Stent SystemGlobeNewswire
- InspireMD to Host KOL Webinar on Carotid Artery Disease Management and the Clinical Benefits of InspireMD’s CGuard Prime Carotid Stent PlatformGlobeNewswire
- InspireMD, Inc. Announces Pricing of $37.5 Million Public OfferingNasdaq
- InspireMD Announces Pricing of $37.5 Million Public OfferingGlobeNewswire
- InspireMD (NSPR) Q3 2026 Earnings Call TranscriptNasdaq
- InspireMD Wins FDA Approval For CGuard Prime In Transcarotid Artery RevascularizationNasdaqNSPR, BRK.A
- InspireMD Announces Proposed Public OfferingGlobeNewswire
InspireMD peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| XTNTXtant Medical Holdings Inc. | 0.21 | -2.82% | $29.49M | vs NSPR |
| NEPHNephros Inc. | 2.61 | -8.10% | $28.37M | vs NSPR |
| TELATELA Bio Inc. | 0.6885 | -5.27% | $31.11M | vs NSPR |
| MDAISpectral AI Inc. Class A | 1.04 | -20.61% | $33.47M | vs NSPR |
| PLRZPolyrizon Ltd. | 9.31 | -8.42% | $22.61M | vs NSPR |
| DAVIDavion Healthcare Plc | 0.9001 | -9.99% | $22.50M | vs NSPR |
| SRTSSensus Healthcare Inc. | 2.26 | -4.24% | $37.20M | vs NSPR |
| PMIPicard Medical Inc. | 6.79 | +7.78% | $18.07M | vs NSPR |
Indexes, lists and sector
InspireMD stock FAQ
What is InspireMD's stock price today?
NSPR last traded at $0.54 as of Nov 20, 4:00 PM EST, down 12.97% on the day. Prices are delayed at least 15 minutes.
Does InspireMD pay a dividend?
No. InspireMD does not currently pay a regular cash dividend.
Who is InspireMD's CEO?
Mr. Marvin L. Slosman is the chief executive officer of InspireMD Inc., which has about 127 employees.
Has NSPR ever split its stock?
Yes. The most recent NSPR stock split was a 1-for-15 split on Apr 27, 2021, one of 5 splits on record.
What is the NSPR 52-week high?
The 52-week high for NSPR is $2.17 and the 52-week low is $0.43. The stock is currently 75.1% below its high.